MedTrace Logo

Mesenchymal Stem Cells (MSCs) - Like Cell Transplantation in Women With Primary Ovarian Insufficiency

NCT03877471 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2021-08-05

No results posted yet for this study

Summary

There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). So far, there was no treatment sufficient enough to cure POI. Cell therapy is a rapidly developing field and have shown immense promise in the treatment of ovarian dysfunction. In this study, the investigator will evaluate the safety of MSC-like cell therapy in women suffering from POI.

Conditions

  • Primary Ovarian Insufficiency

Interventions

GENETIC

Cell therapy

Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.

Sponsors & Collaborators

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • National Natural Science Foundation of China

    collaborator OTHER_GOV

  • Chinese Academy of Sciences

    lead OTHER_GOV

Principal Investigators

  • Hongmei Wang, Doctor · Institute of Zoology, Chinese Academy of Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-03
Primary Completion
2020-07-01
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03877471 on ClinicalTrials.gov